PROfound: Phase III study of the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair gene mutations (HRRm)

Shahneen Sandhu, Maha Hussain, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Kim Chi, Oliver Sartor, Neeraj Agarwal, David Olmos, Antoine Thiery-Vuillemin, Przemyslaw Twardowski, Niven Mehra, Carsten Goessl, Jinyu Kang, Joseph Burgents, Wenting Wu, Alexander Kohlmann, Carrie Adelman, Johann De Bono